Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Mollee

Showing results (81-90 of 145) with videos related to

Pageof 15
Sort By:
British Journal of Haematology|July 5, 2024
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)P Joy Ho, Elizabeth Moore, Cameron Wellard, et al.
Current Oncology (Toronto, Ont.)|February 24, 2022
An Individualized Exercise Intervention for People with Multiple Myeloma-Study Protocol of a Randomized Waitlist-Controlled TrialJennifer L Nicol, Carmel Woodrow, Brent J Cunningham, et al.
Journal of Thrombosis and Haemostasis : JTH|November 16, 2024
Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomized controlled trialGreg Hapgood, Kate Hill, Satomi Okano, et al.
Plos One|January 9, 2020
Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolomeAhmed Mohamed, Joel Collins, Hui Jiang, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)Krystal Bergin, Cameron Wellard, Elizabeth Moore, et al.
Mayo Clinic Proceedings|April 12, 2021
The Clinical Impact of Proteomics in Amyloid TypingMichelle M Hill, Surendra Dasari, Peter Mollee, et al.
Leukemia & Lymphoma|February 26, 2008
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapseSteven Lane, Russell Saal, Peter Mollee, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 19, 2015
Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patientsEmma Taylor, Mark Jones, Matthew J Hourigan, et al.
The Clinical Biochemist. Reviews|March 5, 2019
Paraprotein Sample Exchange in Australia and New Zealand - 2018Nilika Wijeratne, Jillian R Tate, Stephen Du Toit, et al.
Acta Haematologica|October 23, 2022
Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic LeukemiaMelinda Burgess, Colm Keane, Josh Wd Tobin, et al.
Pageof 15

Showing results (81-90 of 145) with videos related to

Sort By:
Pageof 15
British Journal of Haematology|July 5, 2024
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)P Joy Ho, Elizabeth Moore, Cameron Wellard, et al.
Current Oncology (Toronto, Ont.)|February 24, 2022
An Individualized Exercise Intervention for People with Multiple Myeloma-Study Protocol of a Randomized Waitlist-Controlled TrialJennifer L Nicol, Carmel Woodrow, Brent J Cunningham, et al.
Journal of Thrombosis and Haemostasis : JTH|November 16, 2024
Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomized controlled trialGreg Hapgood, Kate Hill, Satomi Okano, et al.
Plos One|January 9, 2020
Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolomeAhmed Mohamed, Joel Collins, Hui Jiang, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)Krystal Bergin, Cameron Wellard, Elizabeth Moore, et al.
Mayo Clinic Proceedings|April 12, 2021
The Clinical Impact of Proteomics in Amyloid TypingMichelle M Hill, Surendra Dasari, Peter Mollee, et al.
Leukemia & Lymphoma|February 26, 2008
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapseSteven Lane, Russell Saal, Peter Mollee, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 19, 2015
Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patientsEmma Taylor, Mark Jones, Matthew J Hourigan, et al.
The Clinical Biochemist. Reviews|March 5, 2019
Paraprotein Sample Exchange in Australia and New Zealand - 2018Nilika Wijeratne, Jillian R Tate, Stephen Du Toit, et al.
Acta Haematologica|October 23, 2022
Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic LeukemiaMelinda Burgess, Colm Keane, Josh Wd Tobin, et al.
Pageof 15